We now view GLP-1 medications and metabolic surgery as complementary treatments rather than competing options
Of its 12 subjects, 83% reported a complete resolution of symptoms after a single round of treatment (injections of compounded BPC-157 totaling 10mg around the areas of bladder inflammation).18 Who should avoid BPC-157
Therapeutics and Clinical Risk Management, 3 (4), 527
Month 3: visible clearing and a more even complexion
These include: Lifestyle interventions (dietary advice, physical activity programmes) Licensed pharmacotherapy such as orlistat, or GLP-1 receptor agonists including semaglutide 2.4 mg (Wegovy, NICE TA875) or tirzepatide (Zepbound) where clinically indicated and available Referral to tier 3 or tier 4 weight management services , including bariatric surgery assessment where appropriate Information on NHS weight management services and eligibility for licensed treatments is available via the NHS website and NICE guidance
Long-term weight loss success comes from sustainable habits, not just medication
